{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Carcinoma&page=2", "query": { "condition": "Gastroesophageal Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-27T01:17:31.707Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00732745", "title": "Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "vandetanib", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2008-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-08-22", "last_synced_at": "2026-06-27T01:17:31.707Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00732745" }, { "nct_id": "NCT04683939", "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Pancreatic Cancer", "Biliary Tract Cancer", "Cholangiocarcinoma", "Metastatic Cancer" ], "interventions": [ { "name": "BNT141", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2022-01-18", "completion_date": "2023-07-24", "has_results": true, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-06-27T01:17:31.707Z", "location_count": 4, "location_summary": "Duarte, California • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04683939" }, { "nct_id": "NCT07594548", "title": "Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Esophageal Adenocarcinoma", "Locally Advanced Gastric Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Metastatic Esophageal Adenocarcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Unresectable Esophageal Adenocarcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Futibatinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2027-09-09", "completion_date": "2031-09-09", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-27T01:17:31.707Z", "location_count": 2, "location_summary": "Chicago, Illinois • Columbus, Ohio", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07594548" }, { "nct_id": "NCT00256321", "title": "Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Carcinoma", "Gastroesophageal Junction Carcinoma" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 4, "start_date": "2004-10", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2019-02-08", "last_synced_at": "2026-06-27T01:17:31.707Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00256321" }, { "nct_id": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Solid Tumors" ], "interventions": [ { "name": "SBT6050", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Silverback Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2020-07-27", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-06-27T01:17:31.707Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460456" }, { "nct_id": "NCT06748872", "title": "EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epithelial Ovarian Cancer", "Gastro-esophageal Junction Cancer", "Soft Tissue Sarcoma (STS)", "Myxoid Liposarcoma", "Synovial Sarcoma" ], "interventions": [ { "name": "Lymphodepletion", "type": "DRUG" }, { "name": "TCR-T cells (MDG1015)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Medigene AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2025-07-01", "completion_date": "2042-08-01", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-06-27T01:17:31.707Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06748872" }, { "nct_id": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Low", "SYD-985", "SYD985", "Vic-trastuzumab Duocarmazine", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic", "HER2 Low Breast Cancer", "GastroEsophageal Cancer", "Gastroesophageal Adenocarcinoma", "Endometrium Tumor", "Ovarian Cancer", "Ovarian Carcinoma", "HER2-positive Gastric Cancer", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2 Low HR Positive", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-07-28", "completion_date": "2021-11-17", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-06-27T01:17:31.707Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04602117" }, { "nct_id": "NCT00290719", "title": "Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "gefitinib", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2005-11", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-06-27T01:17:31.707Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290719" }, { "nct_id": "NCT07517211", "title": "A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clinical Stage I Esophageal Adenocarcinoma AJCC v8", "Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage I Gastric Cancer AJCC v8", "Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage II Gastric Cancer AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Non-Interventional Study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2026-05-01", "completion_date": "2029-05-01", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-06-27T01:17:31.707Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07517211" }, { "nct_id": "NCT04535401", "title": "Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colorectal Carcinoma", "Advanced Digestive System Carcinoma", "Advanced Gastric Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Colorectal Carcinoma", "Metastatic Digestive System Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Stage III Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging", "type": "PROCEDURE" }, { "name": "Elimusertib", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-08-13", "completion_date": "2025-04-29", "has_results": false, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-06-27T01:17:31.707Z", "location_count": 10, "location_summary": "Duarte, California • Bethesda, Maryland • City of Saint Peters, Missouri + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "City of Saint Peters", "state": "Missouri" }, { "city": "Creve Coeur", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04535401" } ] }